-
E-commerce and Physical Stores to Stock Hanmi’s OTC Drugs Following Shanghai Pharma Deal
•
Hanmi Pharmaceutical, a leading South Korean pharmaceutical company, has reportedly entered into a supply agreement with Shanghai Pharma Health Science, a subsidiary of Shanghai Pharmaceutical Group (SHA: 601607). The contract covers the distribution of seven OTC medications, which are planned to be initially marketed through Shanghai Pharma’s e-commerce platform, prior…
-
MSD Partners with Hanmi Pharmaceutical to Develop Combination Therapy for Solid Tumors
•
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a partnership with South Korea’s Hanmi Pharmaceutical (KRX: 128940) to develop a combination therapy using MSD’s top-selling anti-PD-1 therapy Keytruda (pembrolizumab) and Hanmi’s bispecific antibody (BsAb) BH3120 for the treatment of progressive or metastatic solid tumors. The financial details of the…
